Obesity treatment has traditionally been discussed in terms of two broad approaches: lifestyle modification and bariatric surgery. The development of endoscopic bariatric therapies has introduced additional options for patients who require medical intervention but may not be ready for, or suitable for, conventional surgery.

Endoscopic sleeve gastroplasty (ESG) is among the procedures contributing to this shift. Performed through the mouth using a flexible endoscope and a specialized suturing system, ESG reduces stomach capacity without surgically removing gastric tissue.

For Everself, a provider of endoscopic weight-management treatments, ESG is central to a care model combining procedural intervention with nutritional guidance, behavioral support, and longitudinal follow-up.

As professional societies increasingly recognize the role of endoscopic therapies in obesity management, Everself’s approach offers an example of how these procedures can be integrated into a broader clinical treatment pathway.

The expanding role of endoscopic therapies in obesity management

Obesity is a chronic, multifactorial disease associated with metabolic, cardiovascular, and other health complications. Its management may require interventions addressing appetite regulation, energy intake, associated medical conditions, and long-term health behaviors.

Lifestyle modification remains a foundation of treatment. However, dietary and physical activity interventions alone may not produce sufficient or sustained weight reduction for every patient.

Pharmacotherapy and metabolic bariatric surgery provide additional treatment options, although patient eligibility, contraindications, preferences, and treatment burden can influence clinical decisions.

Endoscopic bariatric and metabolic therapies occupy an increasingly recognized position within this continuum.

The 2024 joint guideline from the American Society for Gastrointestinal Endoscopy and European Society of Gastrointestinal Endoscopy suggests endoscopic bariatric and metabolic therapies alongside lifestyle modification for adults with a body mass index (BMI) of at least 30 kg/m², or a BMI of 27 to 29.9 kg/m² with at least one obesity-related comorbidity.

The recommendation is conditional, and the strength of evidence varies by intervention.

For clinicians, these developments emphasize the importance of matching treatment intensity to disease severity, patient characteristics, and long-term management requirements.

How endoscopic sleeve gastroplasty works

ESG is performed under anesthesia using a flexible endoscope introduced through the mouth into the stomach.

A full-thickness endoscopic suturing system places a series of sutures along the gastric wall, drawing tissue together to create a narrower, sleeve-like configuration.

This reduces functional stomach capacity and can influence gastric emptying and sensations of satiety.

Unlike laparoscopic sleeve gastrectomy, ESG does not require surgical resection of the stomach. The gastrointestinal anatomy remains intact, although the stomach’s configuration is altered by the sutures.

The procedure is typically performed in an outpatient setting, and many patients return home on the day of treatment following appropriate observation.

Recovery involves a staged dietary progression, beginning with liquids and advancing to softer foods before regular meals are reintroduced under clinical guidance.

The minimally invasive approach can reduce certain burdens associated with abdominal surgery, but ESG still requires anesthesia, procedural expertise, appropriate patient selection, and monitoring for complications.

Everself’s approach to endoscopic obesity treatment

Everself has positioned endoscopic sleeve gastroplasty as a central component of its obesity-treatment services.

The organization describes its clinical background as connected to the early development of ESG at Harvard Medical School, although specific historical contributions should be distinguished from broader claims about inventing the procedure.

Its Miami-area program is led by Dr. Zaid Rana, a gastroenterologist who serves as Director of Endoscopy at Keralty Hospital and Assistant Professor at the Orlando College of Osteopathic Medicine, according to Everself’s published provider information.

The program offers ESG alongside other weight-management interventions, including intragastric balloon treatment, endoscopic revision procedures, and medication-based care.

Patients considering Everself Miami’s endoscopic sleeve gastroplasty can review the program’s clinical approach, consultation process, procedural setting, and follow-up services. ESG procedures for its Miami-area patients are performed at Surgicare of Miramar in Miramar, Florida.

The care pathway begins with medical assessment and patient selection, followed by the endoscopic procedure and a structured recovery plan.

Everself also describes a 12-month post-procedure support program incorporating registered dietitian consultations, nurse practitioner availability, care coordination, and group-based support.

This model reflects an important consideration in obesity medicine: procedural weight reduction is one component of treatment, while long-term outcomes also depend on nutrition, health behaviors, clinical monitoring, and sustained engagement with care.

Clinical effectiveness and the available evidence

Clinical research has demonstrated that ESG can produce meaningful weight reduction in appropriately selected patients.

The MERIT randomized controlled trial, published in The Lancet in 2022, evaluated ESG combined with lifestyle modification against lifestyle modification alone in adults with class I and II obesity.

At 52 weeks, participants receiving ESG achieved an average total body weight reduction of approximately 13.6%, compared with approximately 0.8% in the control group.

These findings supported the effectiveness of ESG as an additional intervention for obesity management.

However, treatment outcomes vary according to baseline characteristics, procedural technique, adherence to follow-up, and other clinical factors.

Longer-term observational studies have also reported maintenance of clinically meaningful weight loss in some patients over several years, although follow-up completeness and study design should be considered when interpreting durability.

ESG should not be assumed to produce outcomes equivalent to sleeve gastrectomy or modern anti-obesity medications. Direct comparisons require attention to differences in study populations, treatment duration, and outcome definitions.

For clinicians and patients, expected benefits should be discussed alongside procedural risks, alternative treatments, and the likelihood of requiring ongoing weight-management support.

Patient selection and clinical considerations

Patient selection is fundamental to the safe and effective use of ESG.

Assessment generally includes BMI, obesity-related comorbidities, previous weight-management interventions, gastrointestinal history, medication use, and the patient’s ability to participate in follow-up care.

Conditions affecting the stomach or increasing procedural risk may influence eligibility.

Patients with significant gastrointestinal pathology, certain bleeding disorders, or other contraindications may require alternative treatment approaches.

Psychological and nutritional assessment may also be appropriate, particularly when eating behaviors or underlying health conditions could affect treatment outcomes.

The 2025 position statement on endoscopic sleeve gastroplasty published in the Journal of Visceral Surgery recognizes ESG as an effective intervention for obesity while emphasizing patient selection and procedural safety. Although ESG generally has a favorable safety profile in published studies, complications can occur.

Common post-procedure symptoms include nausea, vomiting, abdominal pain, and temporary difficulty tolerating oral intake. Less frequent but potentially serious complications include bleeding, perforation, and intra-abdominal infection.

Patients should receive clear information about these risks, the expected recovery process, and symptoms requiring urgent medical attention.

Why post-procedure management remains essential

The physiological effects of ESG can support reduced food intake, but the procedure does not eliminate the need for nutritional management.

Following treatment, patients typically progress through liquid and soft-food stages before gradually returning to regular meals.

This progression allows the stomach to heal and helps patients adapt to smaller meal volumes.

Protein intake, hydration, and food tolerance require particular attention during recovery. Nutritional counseling can also help patients identify sustainable eating patterns and address behaviors that may interfere with weight management.

Longitudinal follow-up provides opportunities to monitor weight trajectories, metabolic indicators, symptoms, and treatment adherence.

For patients with an inadequate initial response or subsequent weight regain, clinicians may reassess nutritional factors, medications, behavioral needs, and the potential role of additional interventions.

Everself’s 12-month support structure illustrates how an endoscopic treatment program can incorporate follow-up beyond the immediate recovery period.

The availability of coordinated clinical and nutritional care may help patients manage treatment-related adjustments, although the effectiveness of any particular support program should be evaluated using its own outcomes data.

ESG within the future of multidisciplinary obesity care

Obesity management is moving toward a broader range of individualized interventions.

Endoscopic therapies, pharmacological treatments, metabolic bariatric surgery, and lifestyle-based care address different aspects of the disease and may serve different patient populations.

The availability of ESG creates an additional option for patients who meet clinical criteria and prefer an endoscopic approach.

Future research will help clarify optimal patient selection, long-term durability, procedural standardization, and the potential benefits of combining ESG with anti-obesity medications.

For providers such as Everself, the clinical opportunity lies in integrating endoscopic intervention into a comprehensive treatment pathway rather than treating the procedure as a standalone solution.

The development of ESG reflects an expanding understanding of obesity as a condition requiring individualized, sustained care.

Its place within modern treatment will continue to depend on clinical evidence, procedural safety, appropriate patient selection, and the quality of long-term follow-up. Programs that combine these elements may contribute to more coordinated and accessible obesity-management services.

Stay updated, free articles. Join our Telegram channel

Join